UK Regulator Plans New & Higher Fees To Ensure Financial Sustainability
Industry Charges Have Not Been Reviewed Since Brexit
Executive Summary
The MHRA says pharmaceutical and medical device companies should be confident that planned changes to the fees structure will guarantee them “the high-quality service they expect.”